Dare Bioscience, Inc. (DARE) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Dare Bioscience, Inc. is a biopharmaceutical company focused on women's health, with a portfolio including the FDA-approved product XACIATO (commercialized by Organon) and several clinical-stage candidates such as Ovaprene (contraception) and Sildenafil Cream (female sexual arousal disorder). The company operates as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $41,691 | $1,000,000 | $73,431 | $1,000,000 |
| Net Income (Loss) | $(4,702,501) | $(8,299,096) | $1,452,799 | $(25,103,829) |
| Operating Expenses | $4,723,040 | $9,396,415 | $18,136,719 | $26,768,420 |
| Cash & Equivalents (End of Period) | $11,232,609 | $13,894,424 | $11,232,609 | $14,229,424 |
| Working Capital | $1,790,546 | $(2,936,897) | $1,790,546 | $(2,936,897) |
| Accumulated Deficit | $(169,783,232) | $(166,178,469) | $(169,783,232) | $(166,178,469) |
Note: YTD 2024 Net Income includes a one-time gain of approximately $20.4 million from the sale of royalty rights.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped significantly in Q3 2024 compared to Q3 2023 due to the absence of a $1.0 million license fee payment received in the prior year. Current revenue consists primarily of minimal royalty income.
- Expense Reduction: Operating expenses decreased by approximately 50% in Q3 2024 compared to Q3 2023, driven by a 60% reduction in R&D expenses (completion of Sildenafil Cream Phase 2b study) and a 24% reduction in G&A expenses.
- Net Income Turnaround (YTD): The company reported a net income of $1.45 million for the nine months ended Sept 30, 2024, compared to a net loss of $25.1 million in the same period in 2023. This reversal is almost entirely attributable to the $20.4 million net gain recognized from the sale of future royalty and milestone rights to XOMA in April 2024.
- Reverse Stock Split: A 1-for-12 reverse stock split was effected on July 1, 2024, reducing outstanding shares from approximately 101.1 million to 8.5 million.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. Despite the YTD net income, the company does not have sufficient cash to satisfy working capital needs for the next 12 months without raising additional capital.
- Royalty Monetization: In April 2024, the company sold 100% of future royalties and milestones from XACIATO sales (post-April 1, 2024) to XOMA for $22.0 million. Future upside is limited to contingent payments if XOMA collects over $88.0 million.
- Capital Raising: The company entered into a $15.0 million equity line agreement with Lincoln Park Capital Fund in October 2024. It also secured new non-dilutive grants totaling up to $20.7 million from the Bill & Melinda Gates Foundation and ARPA-H in late 2024.
- Nasdaq Compliance: The company received notice in August 2024 of non-compliance with the Nasdaq Minimum Market Value of Listed Securities (MVLS) requirement ($35.0 million). It has until February 10, 2025, to regain compliance or face delisting.
- Unusual Items: The YTD financials are distorted by the non-recurring $20.4 million gain from the royalty sale. Operating cash flow for the nine months ended Sept 30, 2024, was positive ($0.17 million) primarily due to this non-cash gain and changes in working capital.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $11.2 million cash balance against the burn rate, considering the restricted nature of grant funds (approx. $9.8 million deferred liability).
- Nasdaq Status: Monitor the company's progress in meeting the $35.0 million MVLS requirement by the February 10, 2025 deadline to avoid delisting.
- Grant Milestones: Confirm the achievement of milestones required to unlock the remaining funds from the new Gates Foundation ($10.7M) and ARPA-H ($10.0M) grants announced in late 2024.
- Revenue Visibility: Assess the commercial performance of XACIATO by Organon, noting that Dare Bioscience has sold the majority of future royalty rights and will only receive upside payments if specific thresholds are met.
- Capital Needs: Evaluate the likelihood and terms of future equity dilution required to fund the Phase 3 trials for Ovaprene and Sildenafil Cream.